Get started
Author

Q-M. Wang

VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy
2021 · S. Lu, L. Wu, et al. · Annals of Oncology · 34
PDF
OA04.06 Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001)
2024 · J. Wang, J. Duan, et al. · Journal of Thoracic Oncology · 16
PDF
1379P Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations
2023 · J-J. Yang, Y. Zhang, et al. · Annals of Oncology · 10
PDF
198P Adebrelimab with concurrent chemoradiation (cCRT) for limited-stage small cell lung cancer (LS-SCLC): Safety run-in results of a phase III trial
2024 · Y. Cheng, H. Wang, et al. · ESMO Open · 9
62P First-line (1L) camrelizumab plus chemotherapy (chemo) for advanced squamous non-small cell lung cancer (sqNSCLC): 4-yr update from the phase III CameL-sq trial
2024 · C. Zhou, S. Ren, et al. · ESMO Open · 9
196MO Anlotinib plus etoposide/carboplatin (EC) versus placebo plus EC in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): A randomized, double-blind, parallel controlled, phase III trial (ETER 701)
2024 · Y. Cheng, R. Yang, et al. · ESMO Open · 5
61P First-line camrelizumab (Camre) plus carboplatin (Carbo) and pemetrexed (Pem) for advanced non-squamous NSCLC: 5-yr outcomes of CameL phase III study
2024 · C. Zhou, G. Chen, et al. · ESMO Open · 4
84P Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC): 3-year update of the phase III CAPSTONE-1 study
2023 · Y. Cheng, J. Wang, et al. · Immuno-Oncology Technology · 4
PDF
LBA58 Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: Second interim analysis of phase III ORIENT-31 study
2022 · S. Lu, L. Wu, et al. · Annals of Oncology · 4
PDF
336P: Durvalumab (D) as consolidation therapy for limited-stage small-cell lung cancer (LS-SCLC): ADRIATIC China subgroup analysis
2025 · Y. Cheng, Q. Wang, et al. · Journal of Thoracic Oncology · 2
PDF
86P Durvalumab plus olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): Updated efficacy and safety analysis
2023 · Y. Huang, J. Jia, et al. · Immuno-Oncology Technology · 1
PDF
EP12.16: Interim Analysis of Brilliant: Real-World Effectiveness and Safety of 1L Brigatinib for ALK+NSCLC in China
2026 · F. Zhou, L. Wu, et al. · Journal of Thoracic Oncology
P2.246: c-MET Overexpression as an Efficacy Predictive Biomarker in MET Amplification-Driven NSCLC: Explore Analyses of KUNPENG Study
2026 · S.-Y.M. Liu, Y. Yao, et al. · Journal of Thoracic Oncology
EP.12.06 Brilliant First Analysis: A Real-World Study of Characteristics and Safety About Brigatinib as First-Line for Chinese Patients With ALK+ NSCLC
2025 · L. Wang, F. Zhou, et al. · Journal of Thoracic Oncology
Development and Analysis of a Nomogram Based on Prognostic Factors in Locally Advanced Esophagogastric Junction Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy
2025 · W. Yin, Y. Cheng, et al. · International Journal of Radiation Oncology*Biology*Physics
1945P Sacituzumab tirumotecan (sac-TMT) in participants (pts) with previously treated, advanced KRAS-mutant NSCLC: Results from cohort 5d of the SKB264-II-08 study
2025 · T. Zhou, Y. Zhang, et al. · Annals of Oncology
Works count: 17
Citation count: 100
H-index: 5
I10-index: 3
Year
Topic
Type